Treatment of systemic sclerosis

Tyndall, 2010, Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database, Ann Rheum Dis, 69, 1809, 10.1136/ard.2009.114264 Rubio-Rivas, 2014, Mortality and survival in systemic sclerosis: systematic review and meta-analysis, Semin Arthritis Rheum, 44, 208, 10.1016/j.semarthrit.2014.05.010 Kowal-Bielecka, 2017, Update of EULAR recommendations for the treatment of systemic sclerosis, Ann Rheum Dis, 76, 1327, 10.1136/annrheumdis-2016-209909 Lechartier, 2021, Pulmonary arterial hypertension in systemic sclerosis, Presse Med, 50, 10.1016/j.lpm.2021.104062 Guyatt, 2011, GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables, J Clin Epidemiol, 64, 383, 10.1016/j.jclinepi.2010.04.026 Herrick, 2017, Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS), Ann Rheum Dis, 76, 1207, 10.1136/annrheumdis-2016-210503 van den Hoogen, 1996, Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial, Br J Rheumatol, 35, 364, 10.1093/rheumatology/35.4.364 Pope, 2001, A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma, Arthritis Rheum, 44, 1351, 10.1002/1529-0131(200106)44:6<1351::AID-ART227>3.0.CO;2-I Johnson, 2009, Shifting our thinking about uncommon disease trials: the case of methotrexate in scleroderma, J Rheumatol, 36, 323, 10.3899/jrheum.071169 Namas, 2018, Efficacy of mycophenolate mofetil and oral cyclophosphamide on skin thickness: post hoc analyses from two randomized placebo-controlled trials, Arthritis Care Res, 70, 439, 10.1002/acr.23282 Volkmann, 2017, Mycophenolate mofetil versus placebo for systemic sclerosis-related interstitial lung disease: an analysis of scleroderma lung studies I and II, Arthritis Rheumatol, 69, 1451, 10.1002/art.40114 Tashkin, 2006, Cyclophosphamide versus placebo in scleroderma lung disease, N Engl J Med, 354, 2655, 10.1056/NEJMoa055120 Tashkin, 2007, Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease, Am J Respir Crit Care Med, 176, 1026, 10.1164/rccm.200702-326OC Roth, 2011, Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease, Arthritis Rheum, 63, 2797, 10.1002/art.30438 Sharada, 1994, Intravenous dexamethasone pulse therapy in diffuse systemic sclerosis. A randomized placebo-controlled study, Rheumatol Int, 14, 91, 10.1007/BF00300808 Burt, 2011, Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial, Lancet, 378, 498, 10.1016/S0140-6736(11)60982-3 van Laar, 2014, Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial, JAMA, 311, 2490, 10.1001/jama.2014.6368 Sullivan, 2018, Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma, N Engl J Med, 378, 35, 10.1056/NEJMoa1703327 Farge, 2021, Autologous stem cell transplantation in scleroderma, Presse Med, 50, 10.1016/j.lpm.2021.104065 Peytrignet, 2018, Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study, Rheumatology (Oxford), 57, 370, 10.1093/rheumatology/kex410 Rannou, 2017, Personalized physical therapy versus usual care for patients with systemic sclerosis: a randomized controlled trial, Arthritis Care Res, 69, 1050, 10.1002/acr.23098 Goh, 2008, Interstitial lung disease in systemic sclerosis: a simple staging system, Am J Respir Crit Care Med, 177, 1248, 10.1164/rccm.200706-877OC Volkmann, 2019, Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts, Ann Rheum Dis, 78, 122, 10.1136/annrheumdis-2018-213708 Hoyles, 2006, A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma, Arthritis Rheum, 54, 3962, 10.1002/art.22204 Bruni, 2020, Intravenous versus oral cyclophosphamide for lung and/or skin fibrosis in systemic sclerosis: an indirect comparison from EUSTAR and randomised controlled trials, Clin Exp Rheumatol, 38, 161 Tashkin, 2016, Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial, Lancet Respir Med, 4, 708, 10.1016/S2213-2600(16)30152-7 Bérezné, 2008, Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study, J Rheumatol, 35, 1064 Launay, 2016, Mycophenolate mofetil following cyclophosphamide in worsening systemic sclerosis-associated interstitial lung disease, J Sclerod Rel Disord, 1, 234, 10.5301/jsrd.5000205 Distler, 2019, Nintedanib for systemic sclerosis-associated interstitial lung disease, N Engl J Med, 380, 2518, 10.1056/NEJMoa1903076 Bouros, 2002, Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome, Am J Respir Crit Care Med, 165, 1581, 10.1164/rccm.2106012 Guillevin, 2012, Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls, Rheumatology, 51, 460, 10.1093/rheumatology/ker271 Daoussis, 2010, Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study, Rheumatology, 49, 271, 10.1093/rheumatology/kep093 Sircar, 2018, Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial, Rheumatology, 57, 2106, 10.1093/rheumatology/key213 Daoussis, 2017, A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease, Semin Arthritis Rheum, 46, 625, 10.1016/j.semarthrit.2016.10.003 Elhai, 2019, Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study, Ann Rheum Dis, 78, 979, 10.1136/annrheumdis-2018-214816 Ebata, 2021, Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial, Lancet Rheumatol, 3, e489, 10.1016/S2665-9913(21)00107-7 Fraticelli, 2018, Combination therapy with rituximab and mycophenolate mofetil in systemic sclerosis. A single-centre case series study, Clin Exp Rheumatol, 36, 142 Khanna, 2016, Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial, Lancet, 387, 2630, 10.1016/S0140-6736(16)00232-4 Khanna, 2018, Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate), Ann Rheum Dis, 77, 212, 10.1136/annrheumdis-2017-211682 Khanna, 2020, Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Respir Med, 8, 963, 10.1016/S2213-2600(20)30318-0 Maher, 2021, Effect of nintedanib on lung function in patients with systemic sclerosis-associated interstitial lung disease: further analyses of a randomized, double-blind, placebo-controlled trial, Arthritis Rheumatol, 73, 671, 10.1002/art.41576 Highland, 2021, Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial, Lancet Respir Med, 9, 96, 10.1016/S2213-2600(20)30330-1 Crespo, 2016, Lung transplant in patients with scleroderma compared with pulmonary fibrosis. short- and long-term outcomes, Ann Am Thorac Soc, 13, 784, 10.1513/AnnalsATS.201503-177OC Richardson, 2016, Esophageal dilatation and interstitial lung disease in systemic sclerosis: a cross-sectional study, Semin Arthritis Rheum, 46, 109, 10.1016/j.semarthrit.2016.02.004 Rirash, 2017, Calcium channel blockers for primary and secondary Raynaud's phenomenon, Cochrane Database Syst Rev, 12 Curtiss, 2018, A systematic review and meta-analysis of the effects of topical nitrates in the treatment of primary and secondary Raynaud's phenomenon, J Am Acad Dermatol, 78, 10.1016/j.jaad.2018.01.043 Hughes, 2021, Digital ulcers in systemic sclerosis, Presse Med, 50, 10.1016/j.lpm.2021.104064 Rademaker, 1989, Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study, BMJ, 298, 561, 10.1136/bmj.298.6673.561 Negrini, 2019, Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study, Clin Exp Med, 19, 357, 10.1007/s10238-019-00553-y Wigley, 1992, Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis, J Rheumatol, 19, 1407 Wigley, 1994, Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study, Ann Intern Med, 120, 199, 10.7326/0003-4819-120-3-199402010-00004 Tingey, 2013, Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis, Arthritis Care Res, 65, 1460, 10.1002/acr.22018 Guigui, 2020, Treprostinil hydrogel iontophoresis in systemic sclerosis-related digital skin ulcers: a safety study, J Clin Pharmacol, 60, 758, 10.1002/jcph.1574 Korn, 2004, Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist, Arthritis Rheum, 50, 3985, 10.1002/art.20676 Matucci-Cerinic, 2011, Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial, Ann Rheum Dis, 70, 32, 10.1136/ard.2010.130658 Khanna, 2016, Effect of macitentan on the development of new ischemic digital ulcers in patients with systemic sclerosis: DUAL-1 and DUAL-2 randomized clinical trials, JAMA, 315, 1975, 10.1001/jama.2016.5258 Chung, 2014, Effect of the endothelin type A-selective endothelin receptor antagonist ambrisentan on digital ulcers in patients with systemic sclerosis: results of a prospective pilot study, J Am Acad Dermatol, 71, 400, 10.1016/j.jaad.2014.04.028 Hachulla, 2016, Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study, Ann Rheum Dis, 75, 1009, 10.1136/annrheumdis-2014-207001 Shenoy, 2010, Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial, Rheumatology, 49, 2420, 10.1093/rheumatology/keq291 Abou-Raya, 2008, Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers, J Rheumatol, 35, 1801 Denton, 2000, Long-term low molecular weight heparin therapy for severe Raynaud's phenomenon: a pilot study, Clin Exp Rheumatol, 18, 499 Motegi, 2017, Efficacy of botulinum Toxin B Injection for Raynaud's phenomenon and digital ulcers in patients with systemic sclerosis, Acta Derm Venereol, 97, 843, 10.2340/00015555-2665 Bogoch, 2005, Surgery of the hand in patients with systemic sclerosis: outcomes and considerations, J Rheumatol, 32, 642 Steen, 2007, Changes in causes of death in systemic sclerosis, 1972-2002, Ann Rheum Dis, 66, 940, 10.1136/ard.2006.066068 Kim, 2021, Mortality and morbidity in scleroderma renal crisis: a systematic literature review, J Sclerod Rel Disord, 6, 21, 10.1177/2397198320920422 Hudson, 2021, Scleroderma renal crisis, Presse Med, 50, 10.1016/j.lpm.2021.104063 Butler, 2019, Generation of a core set of items to develop classification criteria for scleroderma renal crisis using consensus methodology, Arthritis Rheumatol, 71, 964, 10.1002/art.40809 Fernández-Codina, 2018, Treatment algorithms for systemic sclerosis according to experts, Arthritis Rheumatol, 70, 1820, 10.1002/art.40560 Steen, 2000, Long-term outcomes of scleroderma renal crisis, Ann Intern Med, 133, 600, 10.7326/0003-4819-133-8-200010170-00010 Hudson, 2014, International Scleroderma Renal Crisis Study Investigators. Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis-results from the International Scleroderma Renal Crisis Survey, Semin Arthritis Rheum, 43, 666, 10.1016/j.semarthrit.2013.09.008 Hachulla, 2021, French recommendations for the management of systemic sclerosis, Orphanet J Rare Dis, 16, 322, 10.1186/s13023-021-01844-y Penn, 2007, Scleroderma renal crisis: patient characteristics and long-term outcomes, QJM, 100, 485, 10.1093/qjmed/hcm052 Elhai, 2017, Mapping and predicting mortality from systemic sclerosis, Ann Rheum Dis, 76, 1897, 10.1136/annrheumdis-2017-211448 Bruni, 2021, Cardiac involvement in systemic sclerosis: getting to the heart of the matter, Best Pract Res Clin Rheumatol, 35, 10.1016/j.berh.2021.101668 Parks, 2014, Systemic sclerosis and the heart, Rheum Dis Clin North Am, 40, 87, 10.1016/j.rdc.2013.10.007 Emmanuel, 2016, Current management of the gastrointestinal complications of systemic sclerosis, Nat Rev Gastroenterol Hepatol, 13, 461, 10.1038/nrgastro.2016.99 Hendel, 1992, Omeprazole in the long-term treatment of severe gastro-oesophageal reflux disease in patients with systemic sclerosis, Aliment Pharmacol Ther, 6, 565, 10.1111/j.1365-2036.1992.tb00571.x Shoenut, 1993, The extent and pattern of gastro-oesophageal reflux in patients with scleroderma oesophagus: the effect of low-dose omeprazole, Aliment Pharmacol Ther, 7, 509, 10.1111/j.1365-2036.1993.tb00126.x Muro, 2009, Scoring of reflux symptoms associated with scleroderma and the usefulness of rabeprazole, Clin Exp Rheumatol, 27, 15 Pakozdi, 2009, Does long term therapy with lansoprazole slow progression of oesophageal involvement in systemic sclerosis?, Clin Exp Rheumatol, 27, 5 Foocharoen, 2017, Effectiveness of add-on therapy with domperidone vs alginic acid in proton pump inhibitor partial response gastro-oesophageal reflux disease in systemic sclerosis: randomized placebo-controlled trial, Rheumatology, 56, 214, 10.1093/rheumatology/kew216 Horowitz, 1987, Effects of cisapride on gastric and esophageal emptying in progressive systemic sclerosis, Gastroenterology, 93, 311, 10.1016/0016-5085(87)91020-1 Shah, 2013, Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth, Aliment Pharmacol Ther, 38, 925, 10.1111/apt.12479 Zhong, 2017, Probiotics for preventing and treating small intestinal bacterial overgrowth: a meta-analysis and systematic review of current evidence, J Clin Gastroenterol, 51, 300, 10.1097/MCG.0000000000000814 Pittman, 2018, Treatment of small intestinal bacterial overgrowth in systemic sclerosis: a systematic review, Rheumatology, 57, 1802, 10.1093/rheumatology/key175 García-Collinot, 2020, Effectiveness of saccharomyces boulardii and metronidazole for small intestinal bacterial overgrowth in systemic sclerosis, Dig Dis Sci, 65, 1134, 10.1007/s10620-019-05830-0 Verne, 1995, Effect of octreotide and erythromycin on idiopathic and scleroderma-associated intestinal pseudoobstruction, Digest Dis Sci, 40, 1892, 10.1007/BF02208652 Nikou, 2007, Treatment of small intestinal disease in systemic sclerosis with octreotide: a prospective study in seven patients, JCR, 13, 119 Vigone, 2017, Preliminary safety and efficacy profile of prucalopride in the treatment of systemic sclerosis (SSc)-related intestinal involvement: results from the open label cross-over PROGASS study, Arthritis Res Ther, 19, 145, 10.1186/s13075-017-1340-y Menys, 2016, Comparative quantitative assessment of global small bowel motility using magnetic resonance imaging in chronic intestinal pseudo-obstruction and healthy controls, Neurogastroenterol Motil, 28, 376, 10.1111/nmo.12735 Downes, 2018, Pathophysiology, diagnosis, and management of chronic intestinal pseudo-obstruction, J Clin Gastroenterol, 52, 477, 10.1097/MCG.0000000000001047 Baron, 2010, Screening and therapy for malnutrition and related gastro-intestinal disorders in systemic sclerosis: recommendations of a North American expert panel, Clin Exp Rheumatol, 28, S42 Doerfler, 2017, Medical nutrition therapy for patients with advanced systemic sclerosis (MNT PASS): a pilot intervention study, JPEN J Parenter Enteral Nutr, 41, 678, 10.1177/0148607115597883 Brown, 2008, Home parenteral nutrition–an effective and safe long-term therapy for systemic sclerosis-related intestinal failure, Rheumatology (Oxford), 47, 176, 10.1093/rheumatology/kem329 Morrisroe, 2015, Musculoskeletal manifestations of systemic sclerosis, Rheum Dis Clin North Am, 41, 507, 10.1016/j.rdc.2015.04.011 Au, 2010, Course of dermal ulcers and musculoskeletal involvement in systemic sclerosis patients in the scleroderma lung study, Arthritis Care Res, 62, 1772, 10.1002/acr.20320 Visser, 2009, Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature, Ann Rheum Dis, 68, 1094, 10.1136/ard.2008.092668 Lam, 2007, Efficacy and safety of etanercept in the treatment of scleroderma-associated joint disease, J Rheumatol, 34, 1636 Omair, 2012, Long-term safety and effectiveness of tumour necrosis factor inhibitors in systemic sclerosis patients with inflammatory arthritis, Clin Exp Rheumatol, 30, S55 Denton, 2009, An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis, Ann Rheum Dis, 68, 1433, 10.1136/ard.2008.096123 Distler, 2011, Is there a role for TNFα antagonists in the treatment of SSc? EUSTAR expert consensus development using the Delphi technique, Clin Exp Rheumatol, 29, S40 Dixon, 2010, Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register, Ann Rheum Dis, 69, 1086, 10.1136/ard.2009.120626 Roubille, 2014, Interstitial lung diseases induced or exacerbated by DMARDS and biologic agents in rheumatoid arthritis: a systematic literature review, Semin Arthritis Rheum, 43, 613, 10.1016/j.semarthrit.2013.09.005 Elhai, 2013, Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study, Ann Rheum Dis, 72, 1217, 10.1136/annrheumdis-2012-202657 Ranque, 2009, A descriptive and prognostic study of systemic sclerosis-associated myopathies, Ann Rheum Dis, 68, 1474, 10.1136/ard.2008.095919 Ranque, 2010, Myopathies related to systemic sclerosis: a case-control study of associated clinical and immunological features, Scand J Rheumatol, 39, 498, 10.3109/03009741003774626 Chaigne, 2020, Corticosteroid-sparing benefit of intravenous immunoglobulin in systemic sclerosis-associated myopathy: a comparative study in 52 patients, Autoimmun Rev, 19, 10.1016/j.autrev.2019.102431 Stefanantoni, 2016, Occupational therapy integrated with a self-administered stretching program on systemic sclerosis patients with hand involvement, Clin Exp Rheumatol, 34, 157 Maddali-Bongi, 2011, The rehabilitation of facial involvement in systemic sclerosis: efficacy of the combination of connective tissue massage, Kabat's technique and kinesitherapy: a randomized controlled trial, Rheumatol Int, 31, 895, 10.1007/s00296-010-1382-9 Hudson, 2011, Cigarette smoking in patients with systemic sclerosis, Arthritis Rheum, 63, 230, 10.1002/art.30071 Harrison, 2002, Cigarette smoking as a significant risk factor for digital vascular disease in patients with systemic sclerosis, Arthritis Rheum, 46, 3312, 10.1002/art.10685 Mouthon, 2014, Scleroderma renal crisis, J Rheumatol, 41, 1040, 10.3899/jrheum.131210 Berthet, 2010, Erythromycin as a prokinetic agent: risk factors, J Visc Surg, 147, e13, 10.1016/j.jviscsurg.2010.06.001 Olsson, 2014, Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA), Circulation, 129, 57, 10.1161/CIRCULATIONAHA.113.004526 Preston, 2015, Effect of warfarin treatment on survival of patients with pulmonary arterial hypertension (PAH) in the registry to evaluate early and long-term PAH Disease Management (REVEAL), Circulation, 132, 2403, 10.1161/CIRCULATIONAHA.115.018435 Li, 2020, Epigenomics and transcriptomics of systemic sclerosis CD4+ T cells reveal long-range dysregulation of key inflammatory pathways mediated by disease-associated susceptibility loci, Genome Med, 12, 81, 10.1186/s13073-020-00779-6 Zuo, 2016, Systematic approach to understanding the pathogenesis of systemic sclerosis, Clin Genet Gordon, 2015, Nilotinib (Tasigna™) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial, Arthritis Res Ther, 17, 213, 10.1186/s13075-015-0721-3 Haddon, 2017, Proteomic analysis of sera from individuals with diffuse cutaneous systemic sclerosis reveals a multianalyte signature associated with clinical improvement during imatinib mesylate treatment, J Rheumatol, 44, 631, 10.3899/jrheum.160833 Chakravarty, 2015, Gene expression changes reflect clinical response in a placebo-controlled randomized trial of abatacept in patients with diffuse cutaneous systemic sclerosis, Arthritis Res Ther, 17, 159, 10.1186/s13075-015-0669-3 Campochiaro, 2021, An update on targeted therapies in systemic sclerosis based on a systematic review from the last 3 years, Arthritis Res Ther, 23, 155, 10.1186/s13075-021-02536-5 Whitfield, 2003, Systemic and cell type-specific gene expression patterns in scleroderma skin, Proc Natl Acad Sci USA, 100, 12319, 10.1073/pnas.1635114100 Milano, 2008, Molecular subsets in the gene expression signatures of scleroderma skin, PLoS ONE, 3, e2696, 10.1371/journal.pone.0002696 Assassi, 2015, Dissecting the heterogeneity of skin gene expression patterns in systemic sclerosis, Arthritis Rheumatol, 67, 3016, 10.1002/art.39289 Hinchcliff, 2013, Molecular signatures in skin associated with clinical improvement during mycophenolate treatment in systemic sclerosis, J Invest Dermatol, 133, 1979, 10.1038/jid.2013.130 Christmann, 2014, Association of Interferon- and transforming growth factor β-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis, Arthritis Rheumatol, 66, 714, 10.1002/art.38288 Hsu, 2011, Lung tissues in patients with systemic sclerosis have gene expression patterns unique to pulmonary fibrosis and pulmonary hypertension, Arthritis Rheum, 63, 783, 10.1002/art.30159 Schiopu, 2016, Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study, Arthritis Res Ther, 18, 131, 10.1186/s13075-016-1021-2 Silver, 2019, Safety and tolerability of thrombin inhibition in scleroderma-associated interstitial lung disease, ACR Open Rheumatol, 1, 403, 10.1002/acr2.11049 Pope, 2011, Imatinib in active diffuse cutaneous systemic sclerosis: results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center, Arthritis Rheum, 63, 3547, 10.1002/art.30549 Khanna, 2020, Abatacept in early diffuse cutaneous systemic sclerosis: results of a phase ii investigator-initiated, multicenter, double-blind, randomized, placebo-controlled trial, Arthritis Rheumatol, 72, 125, 10.1002/art.41055 Mantero, 2018, Randomised, double-blind, placebo-controlled trial of IL1-trap, rilonacept, in systemic sclerosis. A phase I/II biomarker trial, Clin Exp Rheumatol, 36, 146 Khanna, 2020, Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial, Ann Rheum Dis, 79, 618, 10.1136/annrheumdis-2019-216823 Khanna, 2016, An open-label, Phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS Trial, J Rheumatol, 43, 1672, 10.3899/jrheum.151322 Acharya, 2020, Efficacy and safety of pirfenidone in systemic sclerosis-related interstitial lung disease-a randomised controlled trial, Rheumatol Int, 40, 703, 10.1007/s00296-020-04565-w Del Papa, 2019, Regional grafting of autologous adipose tissue is effective in inducing prompt healing of indolent digital ulcers in patients with systemic sclerosis: results of a monocentric randomized controlled study, Arthritis Res Ther, 21, 7, 10.1186/s13075-018-1792-8 Mouthon, 2011, Endothelin-1 expression in scleroderma renal crisis, Hum Pathol, 42, 95, 10.1016/j.humpath.2010.05.018 Penn, 2013, Targeting the endothelin axis in scleroderma renal crisis: rationale and feasibility, QJM, 106, 839, 10.1093/qjmed/hct111 Salituri, 2020, Mammalian target of rapamycin is activated in the kidneys of patients with scleroderma renal crisis, Journal of Scleroderma and Related Disorders, 5, 152, 10.1177/2397198319885488 Devresse, 2016, Complement activation and effect of eculizumab in scleroderma renal crisis, Medicine (Baltimore), 95, e4459, 10.1097/MD.0000000000004459 Fretheim, 2020, Fecal microbiota transplantation in systemic sclerosis: a double-blind, placebo-controlled randomized pilot trial, PLoS ONE, 15, 10.1371/journal.pone.0232739